Tag: tyme technologies
September 25, 2019
TYME Launches TYME-88-PANC Trial
The company's TYME-99-Panc trial will evaluate its candidate SM-88 in patients with metastatic pancreatic cancer.
July 7, 2019
5 Top Weekly NASDAQ Biotech & Pharma Stocks: Corvus Soars
Which companies were on the rise last week? We take a look at the top five biotech and pharma stocks... July 5, 2019
TYME Provides Updated Data on TYME-88-Panc Phase II Study
Tyme Technologies (NASDAQ:TYME) has provided an update on its open-label Phase 2 TYME-88-Panc study. As quoted in the press release:... April 3, 2019
TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer
Tyme Technologies (NASDAQ:TYME) has announced the closing of an underwritten registered offering with three existing investors and one new investor... February 25, 2019
TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer
Tyme Technologies (NASDAQ:TYME) has announced it has received design guidance for a registrational trial from the US Food and Drug... January 18, 2019
TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study
Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial...
December 2, 2018